1
|
|
2
|
Duan L, Ma Y, Chi J, Wang X, Wesley AJ, Chen X. The regulatory role of immunosuppressants on immune abnormalities in acute pancreatitis. Biomed Rep 2013; 2:193-198. [PMID: 24649095 DOI: 10.3892/br.2013.208] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2013] [Accepted: 10/04/2013] [Indexed: 02/06/2023] Open
Abstract
The uncontrolled progression of the inflammatory cascade is the main cause underlying the development of multiple organ dysfunction syndrome (MODS) in acute pancreatitis. In this study, we investigated the effects of several immunosuppressants on mitigating the systemic inflammatory reaction syndrome (SIRS) and the compensatory anti-inflammatory response syndrome (CARS) associated with acute pancreatitis. A total of 93 male Sprague Dawley rats were divided into 5 groups: group 1 was the sham group and group 2 underwent laparoscopic intrapancreatic duct injection of sodium taurocholate to induce pancreatitis. The remaining 3 groups were the same as group 2, with the addition of methylprednisolone, cyclophosphamide or methotrexate treatment (metastab, CTX or MTX groups, respectively). Following establishment of the acute pancreatitis model, the serum levels of inflammatory and anti-inflammatory cytokines in groups 2, 3, 4 and 5 were found to be significantly elevated. Following immunosuppressant administration, the levels of all inflammatory and anti-inflammatory cytokines investigated in groups 3, 4 and 5 were decreased compared to those in group 2. The pancreatic amylase levels and pancreatic wet weight (PWW) were also decreased in groups 3, 4 and 5 compared to those in group 2. Therefore, immunosuppressants may reduce inflammation-related cytokine levels in acute pancreatitis and relieve disease progression.
Collapse
Affiliation(s)
- Ligeng Duan
- Department of General Surgery, West China Hospital, West China Medical School, University of Sichuan, Chengdu, Sichuan 610041, P.R. China
| | - Yu Ma
- Department of General Surgery, West China Hospital, West China Medical School, University of Sichuan, Chengdu, Sichuan 610041, P.R. China
| | - Junlin Chi
- Department of General Surgery, West China Hospital, West China Medical School, University of Sichuan, Chengdu, Sichuan 610041, P.R. China
| | - Xu Wang
- Department of Nursing, West China Hospital, West China Medical School, University of Sichuan, Chengdu, Sichuan 610041, P.R. China
| | - Alexander J Wesley
- Department of Surgery, Division of Transplantation, University of Cincinnati Medical Center, Cincinnati, OH 45221-0091, USA
| | - Xiaoli Chen
- Department of General Surgery, West China Hospital, West China Medical School, University of Sichuan, Chengdu, Sichuan 610041, P.R. China
| |
Collapse
|
3
|
Zhang L, Bertucci AM, Ramsey-Goldman R, Harsha-Strong ER, Burt RK, Datta SK. Major pathogenic steps in human lupus can be effectively suppressed by nucleosomal histone peptide epitope-induced regulatory immunity. Clin Immunol 2013; 149:365-78. [PMID: 24211843 DOI: 10.1016/j.clim.2013.08.008] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2013] [Revised: 07/22/2013] [Accepted: 08/14/2013] [Indexed: 02/05/2023]
Abstract
Low-dose tolerance therapy with nucleosomal histone peptide epitopes blocks lupus disease in mouse models, but effect in humans is unknown. Herein, we found that CD4(+)CD25(high)FoxP3(+) or CD4(+)CD45RA(+)FoxP3(low) T-cells, and CD8(+)CD25(+)FoxP3(+) T-cells were all induced durably in PBMCs from inactive lupus patients and healthy subjects by the histone peptide/s themselves, but in active lupus, dexamethasone or hydroxychloroquine unmasked Treg-induction by the peptides. The peptide-induced Treg depended on TGFβ/ALK-5/pSmad 2/3 signaling, and they expressed TGF-β precursor LAP. Lupus patients' sera did not inhibit Treg induction. The peptide epitope-induced T cells markedly suppressed type I IFN related gene expression in lupus PBMC. Finally, the peptide epitopes suppressed pathogenic autoantibody production by PBMC from active lupus patients to baseline levels by additional mechanisms besides Treg induction, and as potently as anti-IL6 antibody. Thus, low-dose histone peptide epitopes block pathogenic autoimmune response in human lupus by multiple mechanisms to restore a stable immunoregulatory state.
Collapse
Affiliation(s)
- Li Zhang
- Divisions of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | | | | | | | | | | |
Collapse
|
4
|
Panopalis P, Clarke AE. Systemic lupus erythematosus: clinical manifestations, treatment and economics. Expert Rev Pharmacoecon Outcomes Res 2012; 6:563-75. [PMID: 20528503 DOI: 10.1586/14737167.6.5.563] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Systemic lupus erythematosus (SLE) is a complex, multisystem disease that is characterized by variable and unpredictable manifestations that are often life-threatening. Although the prognosis has improved dramatically over the past 50 years, individuals with SLE still experience considerable morbidity and undue mortality. Furthermore, since SLE affects a predominantly young population at a critical time in their lives when they are establishing careers and starting families, the economic burden to society can be immense. Only three medications have ever received US FDA approval for use in the treatment of SLE and none have received FDA approval for over 25 years. Currently used therapies may have improved the prognosis but often have undesirable side effects, such as infertility, bone-marrow suppression and infection. Recent advances in our understanding of the disease pathogenesis, coupled with progress in drug development, have led to new therapeutic strategies that will potentially offer an improved side-effect profile and improved efficacy, but will almost certainly be much more expensive than current treatments.
Collapse
Affiliation(s)
- Pantelis Panopalis
- Rheumatology Research Fellow, University of California, San Francisco, UCSF Box 0920, San Francisco, CA 94143-0920, USA.
| | | |
Collapse
|
5
|
|
6
|
Abstract
Lupus nephritis is a challenging clinical condition for which current therapies are unsatisfactory with respect to both remission induction and unwanted toxic effects. Despite intervention, the rates of end-stage renal disease seem to be increasing in the USA. Discoveries over the past decade have greatly improved our understanding of immune activation and effector inflammatory pathways in lupus nephritis; however, this increased understanding has not yet translated into the approval of an effective new therapeutic agent. An analysis of the mechanisms of action of novel immunomodulatory drugs in multiple models of murine lupus clearly shows that interacting networks of immune and effector pathways are recruited as the disease progresses. Reversing established disease by targeting a single cell population or inflammatory pathway is, therefore, difficult once long-lived autoreactive lymphocyte populations are present and peripheral organs are inflamed. Data from murine models of lupus suggest that we need to consider new paradigms for the management of systemic lupus erythematosus that include earlier immune intervention, long-term maintenance therapies and protection of target organs.
Collapse
Affiliation(s)
- Anne Davidson
- Center for Autoimmune and Musculoskeletal Diseases, Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY 11030, USA.
| | | |
Collapse
|
7
|
Eisenberg R. Why can't we find a new treatment for SLE? J Autoimmun 2009; 32:223-30. [PMID: 19329279 DOI: 10.1016/j.jaut.2009.02.006] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2009] [Accepted: 02/11/2009] [Indexed: 12/11/2022]
Abstract
No new therapy for systemic lupus erythematosus has been approved. In the last decade, the development of several novel compounds has been pursued for lupus, but so far nothing has been proven to be effective. This review discusses some of the reasons why it may be so difficult to demonstrate that a novel therapy is effective for this disease. These include the complexity of the disease itself; the lack of reliable outcome measures; our limited understanding of the pathogenesis of the disease; the propensity of lupus patients to have bad outcomes and to react to medicines in unusual ways; the heterogeneity of the patient population; the unpredictable course of disease in individual patients; and the lack of reliable biomarkers. Although some of the tested targeted compounds that are apparently based on strong preclinical and mechanistic data may indeed not be effective therapies for SLE, it is hard not to believe that among the various specific agents now being tested that at least some of them should downregulate the abnormal immunoregulation characteristic of SLE, and thus be clinically effective. We need to be persistent and imaginative in identifying these effective agents and proving their efficacy so that they may be widely used in our lupus populations.
Collapse
Affiliation(s)
- Robert Eisenberg
- Division of Rheumatology, Department of Medicine, 756 BRBII/III, 421 Curie Blvd, University of Pennsylvania, Philadelphia, PA 19104-6160, USA.
| |
Collapse
|
8
|
|
9
|
Abstract
Systemic lupus erythematosus (SLE) is a complex immune disorder in which loss of tolerance to nucleic acid antigens and other crossreactive antigens is associated with the development of pathogenic autoantibodies that damage target organs, including the skin, joints, brain and kidney. New drugs based on modulation of the immune system are currently being developed for the treatment of SLE. Many of these new therapies do not globally suppress the immune system but target specific activation pathways relevant to SLE pathogenesis. Immune modulation in SLE is complicated by differences in the immune defects between patients and at different disease stages. Since both deficiency and hyperactivity of the immune system can give rise to SLE, the ultimate goal for SLE therapy is to restore homeostasis without affecting protective immune responses to pathogens. Here we review recent immunological advances that have enhanced our understanding of SLE pathogenesis and discuss how they may lead to the development of new treatment regimens.
Collapse
|
10
|
|
11
|
Abstract
Despite the tremendous improvement in survival of systemic lupus erythematosus (SLE) in the past few decades, manifestations of the disease that are refractory to conventional therapies and treatment-related complications are still major causes of mortality and morbidity. In recent years, we have seen an explosive development of newer therapeutic modalities for various rheumatic diseases including SLE. Novel therapies for SLE should aim at targeting more specifically the immunopathogenetic pathways to achieve higher efficacy and reduce therapy related toxicities. This article reviews the emerging therapeutic modalities that have been used or are being tried in patients with SLE.
Collapse
Affiliation(s)
- Chi Chiu Mok
- Department of Medicine and Geriatrics, Tuen Mun Hospital, New Territories, Hong Kong, China.
| |
Collapse
|
12
|
Abstract
PURPOSE OF REVIEW Glomerulonephritis is a challenging complication of systemic lupus erythematosus that still results in kidney loss in up to 30% of patients. In this review we highlight the development of integrated efforts to link pathogenesis with disease definition and new therapeutics. RECENT FINDINGS Immune complex deposition in the kidney initiates an inflammatory cascade that causes glomerular disease but there are many modulating factors including genetic predisposition, products of the innate immune system, cytokines, complement and activated cells (both renal and immune). Animal models can help dissect potential disease mechanisms but the study of multiple models will be required since there are multiple subsets of human disease. Recent therapeutic studies in humans address the distinction between therapies for remission induction and remission maintenance. Multiple studies confirm the therapeutic equivalence of mycophenolate mofetil and cyclophosphamide in induction of remission but results are still far from ideal. The next few years should see the testing of new biologic reagents in humans. Another area of interest is the search for noninvasive measures of disease and disease response. SUMMARY Although there has been remarkable progress in our understanding of the immunology and phenotype of lupus nephritis current therapies have insufficient efficacy. As new therapies emerge, improved clinical design coupled with mechanistic studies will be needed to identify agents that may be effective only in some patient subpopulations.
Collapse
Affiliation(s)
- Anne Davidson
- Departments of Medicine, Columbia University Medical Center, 1130 St. Nicholas Avenue, New York, NY 10032, USA.
| | | |
Collapse
|
13
|
CHNG HH. Management of systemic lupus erythematosus in the coming decade: potentials and challenges. ACTA ACUST UNITED AC 2006. [DOI: 10.1111/j.1479-8077.2006.00244.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|